Eisai EMEA
Barbara Poortvliet-Dietz has extensive experience in pharmaceutical marketing, currently serving as Marketing Manager for both the Netherlands and the Benelux region at Eisai EMEA since November 2010, focusing on oncology and neurology. Notable responsibilities include launching key products such as Halaven® for breast cancer and Fycompa® for epilepsy. Prior to this role, Barbara held various positions at Abbott, including Project Manager and Product Specialist in immunology, where significant contributions included the launch of Humira®. Additional experience includes managing marketing operations at Roche Pharmaceuticals for cardiac diseases. Barbara holds a degree from Leiden University, and is pursuing certification in digital marketing to enhance expertise.
This person is not in any offices
Eisai EMEA
3 followers
At Eisai, everything we do is dedicated to giving our first thought to patients and their families through our human health care (hhc) philosophy. We are the European hub of Tokyo-based Eisai Co. Ltd., forming part of a multinational team working across a global network of R&D facilities, manufacturing sites and marketing subsidiaries. Our collective passion and dedication to patient care is the driving force behind our efforts to discover and develop innovative medicines in a variety of therapeutic areas in which a high unmet medical need remains, including oncology and neurology. Our mission is clear; we strive to make a significant long-lasting contribution to society in an ethical, compliant and sustainable way by embodying our hhc philosophy in everything we do. For more information about Eisai in the EMEA region please visit www.eisai.eu Our community guidelines can be found here: https://www.eisai.eu/wp-content/uploads/Community-guidelines-v1.0.pdf For more information about how Eisai processes your data, please refer to our privacy policy here: https://www.eisai.eu/privacy-policy/ --- November 2023 | EMEA-NON-23-00180